Simform announces a $3 million strategic investment to expand its Microsoft Cloud & AI practice, strengthening Azure engineering depth, accelerating IP-led delivery, and scaling co-sell collaboration across key global regions.

ORLANDO, Fla., Feb. 17, 2026 — Simform has strengthened its Microsoft partnership with a $3 million strategic investment aimed at scaling Cloud & AI engineering, accelerating time-to-value through IP & accelerators, and deepening collaboration, co-selling and GTM programs. The initiative builds on Simform’s growing momentum as a multi-specialised Microsoft Solutions Partner with 9 Advanced Specialisations and over 325 certifications, with a goal to double that by the end of the next fiscal year.

“This investment is about scaling what we know works: Engineering DNA, focused solution plays and repeatable motions”, said Prayaag Kasundra, CEO of Simform. “Microsoft Azure has a clear edge for IaaS/PaaS offering for deploying AI apps, Data Platform and Security. We are pairing our Microsoft Cloud & AI expertise on Azure with our product & platform engineering strength to deliver excellence for ISVs, digital natives and highly tech-powered mid-market enterprises”.

Cloud & AI excellence driven by Engineering DNA and repeatable accelerators

Simform has built a formidable reputation as a leading digital engineering company specializing in product and platform engineering with its deeply ingrained Engineering DNA and values like agility, drive, and foresight. With investments into the Microsoft partnership, Simform is looking to bring the same Engineering DNA to Microsoft solutioning.

According to Hiren Dhaduk, CTO at Simform,

“The kind of Azure engineering that drives real impact is built on habits. Architecture reviews that don’t get skipped. Teams that don’t ship and vanish. Environments that don’t break under usage patterns no one planned for.

That’s the engineering maturity we’ve been building quietly at Simform. This investment helps us push it further, across every domain we work in, and every Microsoft engagement we walk into.”

The Lab and Innovation team at Simform has built solution accelerators to be able to have a clear go-to-market edge and reduce time-to-value for customers. Platform Accelerators like Neuvantage for AI-powered App modernisation and TrueMorph for AI-powered Data platform modernisation cover a wide range of scenarios. While Data360, MedNoteDx, and 10+ other accelerators address specific use-cases within Financial Services, Healthcare, Supply chain, and Retail industries.

Simform currently holds Microsoft Solutions Partner designations across four key areas – Digital & App Innovation, Data & AI, Infrastructure, and Security – and nine advanced specializations, including Building AI Apps, Migrate Enterprise Applications, and Analytics on Microsoft Azure. Simform has met all qualification requirements for Azure Expert MSP and is looking forward to attaining Azure Expert MSP designation by March 2026 by completing scheduled audit for the same.

Simform was also recently named a Microsoft Fabric Featured Partner, a recognition reserved for partners with demonstrated capability in building unified, AI-ready data estates on Fabric. It reflects Simform’s continued alignment with Microsoft’s data and AI priorities and its ability to help organizations modernize analytics with speed, scale, and governance.

Building market momentum: Simform at Microsoft Ignite 2025

Simform participated as a sponsor and exhibitor at Microsoft Ignite 2025, where Simform team held productive discussions with engineering and IT executives on how to adopt scalable AI platform practices using AI Foundry and AI-powered legacy application modernization, and building AI-ready, governed data foundations.

Across Microsoft announcement and technical sessions, Simform’s team saw a clear shift toward the “agentic” enterprise and the “Frontier Firm” operating model, with an emphasis on end-to-end AI lifecycle tooling, centralized agent management and observability, and platform capabilities that help organizations scale AI safely and repeatably. Just as importantly, Ignite underscored that security and governance are becoming foundational to AI scale, highlighting expanded Security Copilot agents and new Purview capabilities to strengthen data security and compliance for agents—reinforcing what executives repeatedly emphasized at the booth: speed-to-value matters, but only when paired with strong guardrails for identity, data, and risk.

Scaling co-sell motions and delivering outcomes

Simform’s roadmap for Microsoft FY26 reflects an ambitious push to scale the impact with Microsoft Cloud & AI solutions. Simform is looking to deliver 30+ transformations across infrastructure, applications, data, and AI and building 5+ accelerators aligned to and integrated with Microsoft solutions. Simform has built dedicated teams to scale the Microsoft GTM, including an alliance team to scale the co-sell motions in North America, the UK & Ireland, and Western Europe regions.

“We’ve built a Sales enablement program and pipeline engine aligned with how Microsoft sells,” said Hardik Shah, co-founder/CRO. “Our accelerator-driven offerings reduce the friction in the sales cycles and allow us to differentiate within the competitive partner ecosystem. While our dedicated sales/solutions team leverages the MCEM model, we work closely with Microsoft sellers to simplify value articulation and accelerate opportunities within their customer base.”

With its latest investment and continued alignment with Microsoft’s cloud and AI strategy, Simform is deepening its role as an engineering partner of choice. As enterprise teams move from experimentation to scale, Simform brings the frameworks, accelerators, and co-innovation depth to help Azure initiatives deliver measurable repeatable impact.

To learn more about our direction behind this investment, read this strategy overview published alongside this announcement.

About Simform

Simform is a digital engineering company specializing in Cloud/MACH architectures, Data, AI, ML, and Experience Engineering. With deep expertise across Microsoft Azure, Simform helps high-growth ISVs and tech-enabled enterprises build scalable, future-ready digital platforms through its co-engineering delivery model. With a rich heritage in Microsoft technologies, Simform is recognized as a Solution Partner for Digital and App Innovation, Data & AI, Infrastructure and security. Our team boasts 340+ Azure-certified engineers with specialized skills in .NET, SharePoint, and D365 platforms. With more than 15 years of experience, Simform delivers solutions for high-tech, fintech, healthcare & life sciences, supply chain & logistics, retail & ecommerce, and professional services industries.

Contact:

Prayaag Kasundra
+1-321-237-2727
[email protected]
https://www.simform.com/ 

SOURCE Simform LLC

Round13 Capital investing funds to tackle “a defining challenge of this decade”

TORONTO, Feb. 17, 2026 – Lightworks has secured up to $12 million in financing, led by Round13 Capital, to support the launch of its flagship AI services and accelerate the company’s growth. The consultancy will extend its focus on the world’s largest and most highly regulated enterprises, forging new partnerships to set the standard for managing the deployment of AI agents at scale in regulated domains.

“Round13 Capital’s investment marks a defining milestone,” said John Painter, founder and CEO of Lightworks. “For large, highly regulated enterprises to move AI initiatives from pilots to full scale deployments, they must ensure AI agents can operate safely, transparently, and in alignment with compliance and security frameworks.”

The funding will help Lightworks realize its vision of uniting some of the world’s largest regulated entities with seasoned industry leaders through a new services paradigm – working together to build with and extend industry standards that accelerate the deployment of AI agents at scale for all large enterprises.

“This investment supports Round13 Capital’s guiding mission to back founders and grow the Canadian technology and IT Services ecosystem,” said Wilson Lee, partner at Round13 Capital, a leading venture and growth equity investment firm. “Our past collaborations with John and his team give us great confidence in their ability to establish strategic partnerships and operate within highly complex enterprise environments. Lightworks is tackling a defining challenge of this decade – establishing control, compliance, and visibility for AI at enterprise scale.”

The Lightworks team brings decades of experience advising major institutions on secure and compliant technology adoption and has delivered large-scale programs in North America, Australia, and Asia. For more information, visit light.works.

About Lightworks

Lightworks is a Canadian consultancy specializing in enterprise AI control systems and infrastructure. The firm helps the world’s largest and most highly regulated organizations orchestrate, govern, and secure AI-driven systems. For more information, visit light.works.

About Round13 Capital

Founded in 2013, Round13 Capital is a leading venture and growth equity investment firm based in Toronto, Canada. The firm invests in high-potential companies across a range of sectors, with a focus on supporting their growth and development over the long term. For further information, please visit round13.com.

SOURCE Lightworks

SYDNEY, Feb. 17, 2026 — Fluent Commerce, a global provider of Order Management Systems (OMS), announces today that it has secured A$46m in new funding from Bain Capital. The investment will support continued, profitable global growth, and enable customers to scale faster with new AI-powered capabilities in Fluent Order Management. The capital will:

• Fund further “AI with ROI” investments
• Accelerate customer acquisition
• Support the roll-out of Fluent Connect (new AI integration platform)
• Continue expansion into key international markets

Fluent Commerce CEO, Graham Jackson, said:

“At Fluent Commerce, our goal is to serve our customers with real-time data to enable them to remove profit leaks and to grow. Whether it’s into a new market or launching a new brand or experience, we provide the decision-making engine for AI-ready commerce operations. This investment from Bain Capital enables us to supercharge our international growth and become the AI powerhouse for global brands.”

Fluent Commerce is dedicated to helping companies optimise inventory, move faster and deliver better customer experiences through its scalable, distributed order management platform. Customers include global brands such as Prada Group, L’Oreal, Kingfisher, LVMH and JD Sports.

In January, Fluent Commerce launched its new AI-powered integration platform, ‘Fluent Connect’, which enables retailers and brands to connect Fluent Order Management with critical third-party systems, such as payment gateways, carriers and POS systems, in a matter of hours rather than weeks. By dramatically reducing integration complexity and time-to-value, Fluent Connect allows customers to go live faster, scale more easily, and keep pace with ongoing innovation and growth.

This latest funding highlights investor confidence in Fluent’s long-term vision and continued global expansion. Bain Capital, a global private capital investment firm with over $215 billion (USD) in assets under management, continues to demonstrate its commitment to supporting high-growth companies through its latest transaction with Fluent Commerce.

Paul Kennedy, Partner at Bain Capital, said, “We are excited to partner with Fluent Commerce as it accelerates its global expansion. Fluent has built a best-in-class Order Management platform guided by a proven management team, a focused customer-first strategy, and technology leadership that has earned the trust of leading global brands. Bain Capital’s conviction in Fluent is grounded in our global technology investing experience, which we will continue to apply as we support the company’s ongoing growth.”

This transaction was advised by Neu Capital.

Managing Director from Neu Capital, Cyrus Church, said, “Fluent Commerce is a fantastic Australian success story. It’s been a pleasure arranging this capital as they continue to expand worldwide. “

About Fluent Commerce
Fluent Commerce is a global software company focused on inventory availability data management at scale and distributed order management (DOM) for commerce. Fluent Order Management provides accurate, real-time inventory availability across all locations, order orchestration, fulfillment optimization, fulfillment location management, in-store pick-and-pack, customer service, and reporting.

Fluent Commerce works with organizations such as JD Sports, L’Oréal, Prada Group, ALDO Group, LVMH, Dulux and Kingfisher. For more information, visit fluentcommerce.com

About Bain Capital

Bain Capital is an international investment firm that creates a lasting impact on and for investors, teams, businesses, and communities. Since our foundation in 1984, Bain Capital has leveraged insight and experience to achieve intrinsic growth in several investment areas, including private equity, credit, public equity, venture capital, real estate, life sciences, insurance, and other strategic focus areas. We have 24 offices on 4 continents, over 1,950 employees, with approximately US$ 215 billion in assets under management.

About Neu Capital

Neu Capital is a full service independent debt advisory firm delivering tailored capital solutions to public and private mid-market companies. Neu Capital arranges billions of dollars of transactions across asset-backed securities, corporate finance and special situation structures.

Neu Capital Australia Pty Ltd. | ACN 612 662 692 | Level 4, 333 George Street, Sydney NSW 2000

SOURCE Fluent Commerce

UPPSALA, Sweden, Feb. 17, 2026 — Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance a precision immune therapy for glioblastoma, the most common and aggressive brain tumour which currently lacks effective treatment.

In the project GLIOBREAK, Beactica and KU Leuven are joining forces to advance BEA-17, Beactica’s wholly owned, first-in-class degrader of the epigenetic protein complex LSD1–CoREST, together with a biomarker-driven companion diagnostic developed based on research carried out by Professor Frederik De Smet and colleagues at KU Leuven. GLIOBREAK aims to progress this integrated therapeutic-diagnostic approach from a validated laboratory stage to early clinical readiness, positioning the programme at the forefront of immuno-epigenetic therapies for glioblastoma. The 30-month GLIOBREAK project builds on results from the ongoing EU-financed project GLIOMATCH and will be led and coordinated by Beactica. The project is targeting the completion of IND-enabling studies and submission of a regulatory application to either the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA), positioning BEA-17 for first-in-human clinical trials.

EIC Transition is a Horizon Europe grant scheme that funds activities to mature and validate technology while in parallel developing business and market readiness. Grants of up to EUR 2.5 million are available, covering 100% of the project costs. The funding is non-dilutive to the company’s shareholders. Beactica and KU Leuven’s proposal was one of only 40 selected for financing out of a total of 611 proposals submitted in the most competitive EIC Transition calls ever.

“We are delighted to receive this prestigious EIC Transition award together with our eminent collaborators at KU Leuven. It is a significant validation of our immuno-epigenetic approach to glioblastoma, a disease with devastating outcomes where patients urgently need new therapeutic options. The partnership with KU Leuven and the recognition from the European Innovation Council position BEA-17 at the forefront of precision medicine,” said Beactica’s CEO, Dr. Per Källblad. “This funding enables us to complete our IND-enabling studies and move toward first-in-human trials, bringing this first-in-class LSD1-CoREST degrader closer to patients.”

About glioblastoma (GBM)

GBM is the most common and most aggressive brain tumour. Approximately 35,000 people in the U.S. and Europe are diagnosed with GBM each year. The median overall survival is 15 months, and the five-year overall survival is only 5%.

About BEA-17

BEA-17 is a first-in-class small-molecule targeted degrader of lysine demethylase 1 (LSD1) and its co-factor CoREST. By enhancing antigen presentation, inducing viral mimicry, and reprogramming macrophages toward a pro-inflammatory state, BEA-17 restores immune activity within the tumour microenvironment. In syngeneic animal models of cancer, the candidate drug has shown promising potentiation of immune-modulating treatments across several cancer types, including anti-PD-1 checkpoint inhibitors in colon cancer and standard of care treatment (temozolomide and radiation) in glioblastoma. Pharmacokinetic studies of BEA-17 show good blood-brain-barrier penetration and oral availability. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM). BEA-17 is wholly owned by Beactica Therapeutics.

About Beactica Therapeutics

Beactica Therapeutics AB is a privately held precision medicine company with a pipeline of novel small molecule therapeutics aimed at treating diseases with significant unmet medical need. Beactica’s approach is centered around the Eclipsor™ platform that enables the efficient development of allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit www.beactica.com.

About KU Leuven

Three KU Leuven research teams, led by Prof. Frederik De Smet, Prof. An Coosemans and Prof. Thierry Voet, are collaborating to lay the groundwork for future clinical testing of BEA-17. Prof. De Smet’s team focuses on brain tumor biology and (spatial) single-cell profiling of GBM patient samples and coordinates the GLIOMATCH project, translating patient-derived insights into clinically relevant hypotheses. All single-cell and spatial profiling is embedded within the KU Leuven Institute for Single-cell Omics (LISCO), where Prof. Voet contributes leading expertise in advanced (spatial) single-cell technologies. As part of the KU Leuven Cancer Institute, these molecular insights are functionally tested by Prof. Coosemans’ team using state-of-the-art GBM mouse models and drug profiling platforms, providing a critical translational step toward the clinic. By integrating patient data, single-cell technologies and preclinical validation, this collaboration establishes a focused pipeline aimed at enabling the next generation of clinical testing for GBM at KU Leuven.

Beactica Therapeutics contact
Per Källblad M.Sc. Ph.D.
CEO
[email protected] 
Tel: +46 18 56 08 80

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/beactica-therapeutics-ab/r/beactica-and-ku-leuven-secure-eur-2-5-million-from-the-european-innovation-council-to-advance-orphan,c4308175

The following files are available for download:

TULSA, Okla., Feb. 12, 2026 — The University of Tulsa and Hurricane Ventures have announced an investment in BioReact, an artificial intelligence and analytics platform powering modern bioprocess development and optimization. The funding will be used to accelerate go-to-market efforts and expand BioReact’s product capabilities.

Launched in April 2023, Hurricane Ventures invests in early-stage companies with strategic connections to the university. The fund leverages the university’s knowledge network and resources; advances UTulsa’s innovation ecosystem; and drives success across its portfolio as well as economic growth across the region.

BioReact provides a unified system where teams can bring together data from multiple sources into a structured foundation. Scientists working with bioreactors – specialized containers where cells are grown to develop medicines and vaccines – typically spend four to five hours manually organizing data from devices, spreadsheets and lab notebooks before they can analyze results.

BioReact lets scientists upload data from disparate sources and automatically align datasets, visualizing results in seconds. The platform’s AI analyzes parameters like temperature, pH and nutrient concentrations to identify optimal growth conditions that improve yields, reduce costs and shorten development cycles. The platform requires no coding expertise and has applications across industries like biopharma, industrial biotech and synthetic biology.

“The support from The University of Tulsa and Hurricane Ventures allows us to accelerate development of software that genuinely serves scientists. Beyond the capital, access to UTulsa’s exceptional biotech talent gives us a unique advantage in refining the product alongside real scientific expertise, ensuring BioReact continues to deliver meaningful, practical improvements for teams running complex bioprocesses,” said Mitchell Castetter, CEO and co-founder.

Castetter has spent more than a decade in biotech sales at Beckman Coulter and Cytena. His co-founder Joanna Lipinski, Ph.D., brings over 20 years of experience spanning high-tech and biotech, with a career focused on building advanced software and data platforms that power modern scientific research.

“We are excited to support founders Mitchell and Joanna as they modernize bioprocess development and help scientists work more efficiently,” said Chris Wright, assistant vice president and leader of UTulsa’s Center for Innovation & Entrepreneurship.

BioReact is the 12th company to receive support from Hurricane Ventures.

“We’re thrilled to back this team as they modernize the bioprocess workflow and ultimately help accelerate the development of pharmaceuticals and other critical products,” said Connor Sitton, director of Hurricane Ventures.

SOURCE The University of Tulsa

“Procurement teams are being asked to manage increasingly complex supply chains with tools that were never designed for the pace or scale of today’s trade,” said Tim Spencer, Co-founder and CEO of Didero. “Didero’s AI agents handle the day-to-day operational work of procurement, allowing teams to spend less time chasing emails and exceptions and more time focusing on strategic decisions.”

Procurement teams at manufacturers and distributors manage thousands of supplier interactions across email, ERP systems, and spreadsheets, much of it still handled manually. Didero deploys AI agents that operate inside those existing systems and communications, building contextual understanding of products, pricing, policies, and historical order data. Within weeks of integration, these agents take on core procurement workflows like supplier communication, order tracking, and exception handling, improving order visibility and cycle times while reducing operational overhead.

“Procurement has long been weighed down by repetitive, high-friction work that has proven difficult to automate at scale,” said Kristina Shen, Managing Partner at Chemistry. “Didero applies AI agents directly to that operational layer in a way that materially changes how supply chain teams work and what they can achieve. We believe this will become core infrastructure for companies that need to move faster, operate with more visibility, and adapt to increasingly complex global trade.”

As Didero scales across manufacturers and distributors, its ability to deliver operational impact quickly has resonated with investors focused on execution and customer adoption.

“Didero is delivering efficiency gains and cost reductions for manufacturers and distributors, all with minimal implementation overhead. That value proposition is really changing how operators in more industrial industries see AI helping their businesses,” said Taylor Brandt, Partner at Headline. “We haven’t seen many AI-native supply chain players with as many deployments or such exceptional customer feedback, which made this feel like a turning point for a once in a multi decade transformation.”

Didero’s integration-first approach has also made the company a natural fit within the Microsoft ecosystem, where many enterprises already run core supply chain and finance operations.

“Agentic AI unlocks a new level of automation and efficiency in procurement that simply wasn’t possible with older technologies, and Didero is uniquely positioned to deliver that impact at scale,” said Cheryl Cheng, Managing Partner at M12, Microsoft’s Venture Fund. “With Microsoft’s large footprint of manufacturing customers, we see our relationship with Didero as a way to streamline procurement workflows that offer high strategic value.”

Didero is expanding its product development, engineering, go-to-market, and customer enablement teams to support growing customer demand. The company is hiring across enterprise sales, customer success, and technical roles as it scales deployments with manufacturers and distributors. Didero also plans to build on its core procurement offering over time, extending its platform to support adjacent workflows such as sourcing and payments.

Founded in December 2023, Didero is embedded with more than 30 customers to date, working with manufacturers and distributors to modernize procurement operations across complex supply chains.

“Didero’s AI agents were autonomously executing mission-critical procurement tasks for us within weeks,” said Stephen Sharr, VP of Procurement, Logistics and Contract Manufacturing at Footprint. “I’ve deployed a lot of software over my career, and I’ve never seen anything like the speed or impact of this.”

About Didero
Didero uses AI agents to automate enterprise procurement for manufacturers and distributors. The company’s platform operates inside existing systems and communications to handle core procurement workflows, helping customers improve visibility, shorten order cycles, and reduce operational overhead across complex supply chains. To learn more about Didero or explore career opportunities, visit www.didero.ai. 

SOURCE Didero

SAN FRANCISCO, Feb. 12, 2026 — As global investment markets adjust to higher interest rates and more disciplined capital allocation, serial entrepreneur and investor Jess Mah, also known as Jessica Mah, says today’s challenging environment is producing stronger, more resilient founders.

Mah, founder and CEO of venture firm Mahway, is based in San Francisco and works closely with startups across artificial intelligence, fintech, biotech, and legal technology. With more than a decade of experience building and backing companies, she believes the current funding slowdown represents a healthy correction for the startup ecosystem.

“Capital isn’t disappearing. It’s getting smarter,” said Mah. “Investors are becoming more thoughtful about where they put their money and which founders they support.”

After years of record venture fundraising and inflated valuations, private investors and institutional funds are slowing their pace and prioritizing companies with demonstrated revenue, customer traction, and sustainable business models. According to Mah, this shift is reshaping how founders approach growth and execution.

“The money is still there,” said Jessica Mah. “It’s just not moving the same way it used to.”

Mah began her entrepreneurial journey in middle school, launching a six-figure business before graduating high school. She later became the youngest woman accepted into Y Combinator and went on to build multiple venture-backed companies. Through Mahway, she now invests in what she calls “high-conviction founders” who combine industry expertise with disciplined execution.

She attributes today’s tighter market conditions in part to rising interest rates and the availability of safer investment alternatives, which have reduced speculative startup funding. As a result, founders are being challenged to prove real value earlier in their company’s lifecycle.

“Some founders had never experienced a normal market before,” Mah said. “Now they’re learning what it means to build when capital actually costs something.”

At the same time, Mah notes that artificial intelligence has created both opportunity and complexity. While AI is accelerating product development and operational efficiency, it has also led to market saturation in certain segments, making differentiation more difficult.

“Every week, something new is coming out with AI,” said Jess Mah. “The best opportunities are still ahead of us.”

Despite tighter funding conditions, Mah sees continued momentum for startups using AI to solve measurable, high-impact problems for enterprise and institutional customers. She points to women’s health, regulatory compliance, financial services, insurtech, and workforce technology as major growth areas.

“Investors want to see founders solving real problems for customers who will pay,” Mah said. “Not theoretical problems for hypothetical markets.“

Through Mahway, Mah supports companies that leverage lean teams, automation, and data intelligence to compete more effectively against larger incumbents. She believes this efficiency-driven model is becoming the new standard for scalable startups.

“Today, small teams with the right AI tools can accomplish in months what used to take years,” said Jessica Mah.

Beyond financial performance, Mah emphasizes long-term sustainability, founder well-being, and inclusive leadership. She is a vocal advocate for mental health awareness in entrepreneurship and increased funding access for women-led companies.

“I want to show that you can build great companies and still have a healthy personal life,” Mah said. “Longevity matters more than hype.”

Looking ahead, Mah believes the current market cycle will ultimately strengthen the startup ecosystem by rewarding disciplined leadership and long-term thinking.

“The founders who survive this period will build companies that last,” said Jess Mah. “That’s what playing the long game really means.”

About Mahway

Mahway is a San Francisco–based venture and investment firm founded by Jess Mah (Jessica Mah). The firm partners with high-conviction founders across artificial intelligence, fintech, biotech, legal technology, and emerging industries. Mahway focuses on building durable, AI-enabled companies designed for long-term growth and impact.

For media inquiries, interviews, or partnership opportunities:

Email: [email protected] 
Website: www.mahway.com 

Photo – https://mma.prnewswire.com/media/2877467/Mahway.jpg

SOURCE Mahway

Funding accelerates growth for AI-driven network delivering trusted, seamless bill-only transactions for health systems and suppliers

SCOTTSDALE, Ariz., Feb. 12, 2026 — In Revenue Capital, the first operator-immersive venture capital firm, today announces its participation in a $3 million funding round for Helia Care, alongside Habanero Ventures. The round caps off a record growth year for Helia’s revolutionary network for bill-only medical device procurement within health systems, suppliers, and distributors. With this investment, Helia plans to continue expanding adoption across health systems and suppliers as healthcare organizations face increasing pressure to control costs while maintaining clinical efficiency.

Helia is an AI-enabled procurement platform initially deployed for bill-only transactions, which occur when hospitals must order critical, high-cost medical devices and supplies at the time of surgery or treatment rather than rely on existing inventory. Industry reporting shows that 50% of hospital supply chain spending occurs via bill-only transactions, which accounts for 60% of net patient revenues, further underscoring the criticality of this traditionally manual and error-prone process.

“For us, this investment was driven by more than growth; it was driven by results,” said Justin Gray, co-founder and managing partner of In Revenue Capital. “Helia saves hospitals an average of $1.85 million per location, turning its strategic vision into clear, measurable savings. The company has spent years building a true two-sided network that includes the world’s leading medical device suppliers. With the supplier ecosystem now in place, health systems and suppliers are seeing immediate value and expanding adoption across their organizations. The business fundamentals are very strong.”

Helia’s platform aligns clinical ordering with existing supplier contracts, reducing errors, off-contract purchasing, and pricing discrepancies that contribute to fraud, waste, and abuse. Because the software is embedded directly into hospital workflows, the financial impact is immediate and ongoing, making the solution incredibly scalable once deployed.

“The hardest part of building a true healthcare network is earning trust on both sides,” said Grant Siders, founder and chief executive officer of Helia Care. “By aligning clinical workflows with contracted supplier economics, we’ve created a platform where hospitals, suppliers, and distributors all win, and where expansion becomes a natural byproduct of delivered value.”

In Revenue Capital’s decision to participate in the round reflects its broader investment approach of backing companies that prove disciplined execution along with efficient operations, making them truly unique in an era where AI value is often fuzzy at best. After building strong fundamental technology, validating hospital workflows and needs, and converting early deployments into systemwide adoption, Helia represents the type of proven-value profile the firm looks for when pairing capital with the inherent power of embedded go-to-market support.

“What stood out to us is that Helia is not just solving a technical problem; it is solving an execution problem that hospitals and suppliers deal with every day,” said Craig Coppola, founder and manager, Habanero Ventures. “The team has built the supplier relationships, proven adoption across real health systems, and demonstrated measurable savings, which is exactly what you want to see before scaling go-to-market in a category this complex.”

Unlike traditional bill-only management approaches that rely on services offerings or business process outsourcing, Helia delivers this capability through software and a true two-sided network. This allows hospitals and major suppliers to operate on a shared platform built specifically for high-cost, time-sensitive medical device procurement, introducing a new model for managing one of the most complex segments of healthcare purchasing.

To learn more, please visit https://heliacare.com.

About In Revenue Capital
In Revenue Capital was founded on the fundamental maxim that Go-to-Market excellence forms the last true moat in startups. We partner with top-tier Venture Capital firms to identify the best early-stage B2B Vertical SaaS startups for co-investment. Beyond capital, we provide embedded go-to-market expertise in a true value-add model we call ‘Operator Immersive.’ This sleeves-up, hands-on approach enables our portfolio companies to outpace their peers and win markets, while our partner VCs and Limited Partners de-risk their investments.

About Habanero Ventures
Founded in 1998 by R. Craig Coppola, Habanero Ventures invests in people and companies as an angel investor. Habanero Ventures is dedicated to helping startups and entrepreneurs create world-class companies. Habanero Ventures provides equity, guidance, wisdom, and resources, creating a unique path for growth and ultimately success. For more information, reach out to Craig Coppola directly https://www.linkedin.com/in/craigcoppola/  

SOURCE In Revenue Capital

SAN FRANCISCO, Feb. 12, 2026 — Yosemite, a venture capital firm dedicated to making cancer non-lethal through a combination of academic philanthropy and for-profit investing, has deployed more than $18 million in grants through a donor-advised charitable vehicle since the firm’s launch in 2023.

This philanthropic support operates alongside Yosemite’s venture investing and is directed toward early-stage research that precedes traditional investment, helping advance new scientific ideas and approaches to cancer care at a time when academic researchers face an increasingly competitive funding landscape.

“Academic seed funding is essential to the evolution of cancer care,” said Reed Jobs, Founder and Managing Partner of Yosemite. “Our donor-advised fund strategy enables us and our community to support ambitious, foundational work at its earliest stages and help move promising science toward translation.”

One example included preclinical research led by Craig Crews at Yale, which contributed to foundational insights behind the formation of Quarry Thera, a biotechnology company developing small molecule drugs that modulate protein interactions in completely novel ways to treat cancer and autoimmune diseases.

Collaboration with the American Cancer Society

A cornerstone of Yosemite’s grantmaking activity is its ongoing partnership with the American Cancer Society, one of the largest and most established cancer research funders in the United States. Through this collaboration, the organizations annually identify emerging and high-impact research areas based on mutual scientific interest.

“We are excited to partner with Yosemite for the second year, expanding our ability to fund innovative projects that can have real and practical implications for cancer patients,” said Bill Dahut, M.D., Chief Scientific Officer at the American Cancer Society.

Past focus areas have included artificial intelligence in cancer research, the tumor microenvironment, cancer vaccines, and cancer-targeted toxin delivery. Awardees in the 2025 American Cancer Society-Yosemite grant cycle include a mix of emerging investigators and established luminaries, including Carolyn Bertozzi, Jennifer Doudna, William Kaelin, Kai Wucherpfennig, and Stephen Elledge.

The partnership has already demonstrated early scientific impact. One supported project led by Jeremiah Johnson’s group at MIT, recently published in Nature Biotechnology, developed a next-generation antibody-based drug delivery approach that allows each antibody to carry more drug molecules than conventional antibody-drug conjugates, demonstrating stronger anti-tumor activity in preclinical models of breast and ovarian cancer.

“This support allowed us to pursue a high-risk, high-reward direction that would have been difficult to fund otherwise,” Johnson said. “The ACS-Yosemite partnership created the flexibility and momentum needed to move the work quickly from concept to publication.”

Directed Healthcare Grants

In addition to supporting foundational scientific discovery through its collaboration with the American Cancer Society, Yosemite, through a donor-advised fund platform, also supports healthcare initiatives focused on improving cancer-care delivery at leading institutions, including Mayo Clinic and City of Hope. 

These initiatives address practical challenges in oncology care and span innovation across the cancer care continuum. Areas of focus include:

• Improving diagnostic accuracy and efficiency through AI-enabled tools
• Using new digital and physiological signals to monitor patient health and predict disease risk
• Informing care and treatment decisions through integrated data and clinical intelligence

At Mayo Clinic, the funding is being applied across clinical programs and research settings.

“This philanthropic investment will advance Mayo Clinic’s work to transform cancer research and care, from early detection through survivorship,” said Cheryl Willman, M.D., Stephen and Barbara Slaggie Executive Director of Mayo Clinic Cancer Programs and Director of the Mayo Clinic Comprehensive Cancer Center. “We appreciate the support that makes this important work possible.”

At City of Hope, the support is helping accelerate the translation of research into routine clinical practice.

“A partnership–driven approach aligns with City of Hope’s mission to translate discovery into impact at a national scale. By supporting ambitious and innovative teams in AI, diagnostics, and care delivery, we can accelerate the integration of breakthrough research into everyday clinical practice to the benefit of patients who need lifesaving care today,” said John Carpten, Ph.D., Chief Scientific Officer at City of Hope, and Director of the City of Hope Comprehensive Cancer Center.

Looking Ahead

Through its hybrid grant-making and investment strategy, Yosemite will remain an active vehicle for supporting early-stage cancer research and healthcare initiatives. As academic funding becomes increasingly competitive, philanthropic support is expected to remain an important source of funding for foundational research that informs future translational and clinical efforts. To learn more, contact [email protected].

About Yosemite
Yosemite partners with leading researchers and visionary entrepreneurs working to make cancer non-lethal within our lifetime. Through a donor-advised fund and investment platform, Yosemite supports innovation across the oncology ecosystem — from early academic research to later-stage companies — advancing new therapies and technologies that improve patient outcomes. Leveraging its deep scientific network, Yosemite builds and finances companies translating breakthrough discoveries into better therapies and patient experiences to improve the health and lives of cancer patients. For more information, please visit: yosemite.co

Media Contact
Theo Gardner-Puschak – [email protected]
Carlos Peraza – [email protected]

SOURCE Yosemite